398results about "Tumor necrosis factor" patented technology

The present invention relates to polypeptide consisting of three TNF homology domains of TNF-ligand family members proteins (THD) that specifically bind to the extracellular part of TNFR2, wherein C-terminal and N-terminal reference points are defined by consensus sequences. The THIDs are linked by short stretches of further C-terminal and / or N-terminal amino acids of the THD or variants thereof as well as by peptide linkers. These peptides have an improved stability. Furthermore the invention relates to polypeptide multimers comprising several of the polypeptides of the present invention.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

To provide a new composition for increasing expression of the Klotho gene and an application thereof.SOLUTION: The present disclosure provides, in one aspect, the following invention: a composition for enhancing expression of the human Klotho / KL gene, the composition comprising at least a portion of a protein belonging to the TNF superfamily or a nucleic acid encoding at least a portion of the protein.SELECTED DRAWING: None

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

The present disclosure relates to a tumour necrosis factor receptor 2 (TNFR2) agonist polypeptide comprising (i) a TNFR2 binding domain comprising three TNF homology domains (THD) that specifically bind to TNFR2; and (ii) an Fc domain. The disclosure further relates to a TNFR2 agonist for use in the treatment and / or prevention of - for example - chronic pain or multiple sclerosis.

The present disclosure provides, in one aspect, bifunctional compounds useful for promoting or enhancing degradation of certain circulating proteins. In another aspect, the present disclosure provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment and / or management of a disease and / or disorder entails degradation, clearance, or reduction of the concentration of circulating proteins or autoantibodies in a subject. Thus, in certain embodiments, administration of compounds of the present disclosure to a subject clears or reduces the circulating concentration of circulating proteins or autoantibodies, thus treating, ameliorating or preventing diseases and / or disorders. In certain embodiments, the circulating protein is a TNF.

The invention provides an anti-TNF (Tumor Necrosis Factor) alpha nano antibody and application thereof, and relates to a nano antibody, polypeptide containing the nano antibody, application of the nano antibody and the like, a variable region in an amino acid sequence of the nano antibody comprises three complementarity determining regions CDR and a framework region FR, the complementarity determining regions CDR comprise a complementarity determining region CDR1, a complementarity determining region CDR2 and a complementarity determining region CDR3, the main sites participating in antigen recognition and binding are RXXXXXE on CDR1 and ATYSDSPWNXXSFYXLSGVGA on CDR3, and the nano antibody and the polypeptide thereof have very high affinity and activity, can specifically recognize and bind TNF alpha, and can be used for adsorption, removal, detection and the like of TNF alpha.

The present disclosure relates to T cells engineered to comprise a heterologous nucleic acid sequence encoding a double mutant transforming growth factor [beta] 1 (dmTGFB1) under the control of a promoter sequence. In certain embodiments, the cells further comprise modifications of an endogenous nucleic acid sequence encoding TNFA, e.g., knockdown; modifications, e.g., knock-down, of an endogenous nucleic acid sequence encoding IFNG or IL17A; and insertion of sequences encoding regulatory T cell promoting molecules, and compositions and uses thereof.

Provided herein are methods for producing natural and reconstructed hyaluronic acid (HA) complexes containing pentraxin-3 (PTX3) and heavy chain 1 (HC1) of inter-alpha inhibitor (IαI). Provided are compositions containing the complexes and methods of treatment using the complexes. Also provided are combinations and kits for implementing the methods.

Provided herein is disclosure of a recombinant bifunctional protein or polypeptide capable of binding to a cell surface receptor for lysosome targeting that is made up of an N-glycosylated peptide comprising at least one N-glycan group and a protein of interest, or antibody or antibody fragment capable of binding to a protein of interest. Also provided herein are methods for producing said recombinant bifunctional protein. Also provided herein are methods for lysosomal degradation of a protein of interest comprising introducing to a cell the peptide sequence of the recombinant bifunctional protein.

The present invention is directed to anti-CTHRC1 fusion proteins, compositions comprising the same, and methods of using such anti-CTHRC1 fusion proteins and compositions for the prevention and / or treatment of cancer. Wherein anti-CTHRC1 fusion proteins comprise a first domain comprising a CTHRC1 binding moiety; and a second domain comprising a T cell engager; preferably wherein the T cell engager comprises a ligand for a receptor expressed on a T cell.

The presently disclosed subject matter relates to tumor infiltrated T cells induced by oncolytic virus (“OV-induced T cells”), methods of making and using said OV-induced T cells for an adoptive T-cell therapy. The presently disclosed subject matter further relates to oncolytic viruses and armed oncolytic viruses, methods of making and using said oncolytic viruses, as well as pharmaceutical compositions and kits comprising said oncolytic viruses.

Provided are multispecific binding agents comprising anti-fibroblast activation protein (FAP) antibodies and one or more monovalent ligand traps. The multispecific binding agents may be used in therapeutic methods for treating FAP associated diseases or disorders.

The described invention provides tumor cell vaccines comprising genetically modified tumor cell lines of specific tumor types that stably express high levels of two or more immune modulators. According to some embodiments, immunogenic amounts of tumor cell line variants can be selected for co-expression of two or more membrane and soluble forms of GM-CSF and Flt-3L peptides, along with recombinant membrane-expressed IgG1, CD40L, and TNF-alpha, which are effective in eliciting anti-tumor immune responses compared to the parental, unmodified tumor cell line, as measured in vitro by a one-way mixed lymphocyte tumor response assay using human peripheral blood mononuclear cells and the genetically modified allogeneic cell vaccine candidate. According to some embodiments, the tumor cell vaccine candidate induces an immune response in recipient cancer patients that cross-reacts with the patient's own (autologous) tumor cells, an effect sufficient to result in enhanced anti-tumor immunity that contributes to prolonged survival of vaccinated patient cohorts compared to corresponding unvaccinated patient cohorts.

The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present disclosure provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment and / or management of a disease and / or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the disclosure to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and / or disorder. In certain embodiments, the circulating protein is TNF.

The present invention relates to multispecific antigen binding proteins that comprise an antigen-binding regions specific for a tumor-associated antigen (TAA), an antigen-binding region that specifically binds an epitope of a γδ T cell receptor (TCR), a γδ T cell-activating cytokine, and optionally, a γδ T cell co-stimulatory agonist. The γδ T cell-activating cytokine preferably is at least 5 one of an interleukin 21 receptor (IL21R) agonist and an interleukin 15 receptor (IL15R) agonist. The γδ T cell co-stimulatory agonist cytokine preferably is at least one of a 4-1BB agonist, a CD27 agonist and a GITR agonist. The multispecific antigen binding proteins of the invention specifically redirect and activate γδ T cell to lyse targeted tumor cells. The invention further relates to the use of such multispecific antigen binding proteins in the treatment of cancer, preferably a cancer 10 expressing the TAA.

Provided herein are immunoconjugate molecules containing a TNF-α polypeptide and a masking moiety capable of inhibiting and activating the TNF-α activity under suitable conditions. Also provided herein are methods for producing the immunoconjugate molecules. Finally, provided herein are the therapeutic uses of the immunoconjugate molecules due to their modulating effects on the immune system for treating diseases such as cancer and other chronic infectious diseases.

Provided herein are macromolecules that conditionally induce a cellular effector function (e.g., a biological or therapeutic activity) based on the presence of a disease signature ligand, compositions comprising the same, and methods of using the same.

The present disclosure relates to antibody molecules that bind to epidermal growth factor receptor (EGFR) and / or c-Met, and conjugates containing these antibody molecules. The antibody molecules and conjugates have application, for example, in the treatment of cancer.

The application relates to the technical field of biological medicine, in particular to a medicine for combined treatment of tumors by using a recombinant oncolytic virus and a small-molecule anticancer drug. The method comprises the following steps: combined treatment of tumors by using a recombinant oncolytic virus and a small-molecule anticancer drug; the small-molecule anticancer drug is a small-molecule anticancer drug targeting Parp; the recombinant oncolytic virus comprises M protein, G protein, N protein, P protein and L protein after site-directed mutagenesis. The application can kill tumor cells by using a recombinant oncolytic virus and a small-molecule anticancer drug, and the curative effect is 1+1>2.

Provided herein are novel constructs comprising gold nanoparticles bound to two types of cytokines, wherein the two types of cytokines comprise Tumor Necrosis Factor alpha (TNF ) and a cytokine selected from the group consisting of Interferon gamma (IFN ) and lnterleukin-12. Further provided is a method for treating cancer in a subject in need thereof.

An agent is described that includes a plant virus particle or VLP conjugate to TRAIL. Associating TRAIL with the plant virus particle or VLP serves to both target cancer cells and induce their apoptosis. The agent can therefore be used for a method of treating cancer in a subject.

Immunogenic fusion proteins against infectious animal diseases. A fusion protein is disclosed, which comprises a CD40-binding domain; an antigen of a pathogen; a translocation domain located between the CD40-binding domain and the antigen, and a furin and / or cathepsin L cleavage site located between the CD40-binding domain and the translocation domain. Also disclosed are pharmaceutical compositions, expression vectors and use of the fusion proteins of the invention for eliciting an antigen-specific cell-mediated immune response, or for reducing, inhibiting, treating and / or ameliorating an infectious animal disease caused by a pathogen in an animal in need thereof

Described herein are methods, systems, compositions, and kits useful for the diagnosis and / or treatment of a disease or condition in a subject. The present disclosure relates to methods and systems for identifying and stratifying patients suitable for treatment with a modulator of RNASET2, as described herein.

Provided are conjugates of an arginine deiminase (ADI) and a Tumor Necrosis Factor (TNF) superfamily ligand, and related compositions and methods of use thereof. Also provided are conjugates of a hexameric polypeptide and a trimeric polypeptide, conjugates of a first and second trimeric polypeptide, and related compositions and methods of use thereof.

The present invention relates to modified myeloid cells or iPS or HSCs comprising a chimeric antigen receptor (CAR), or modified induced pluripotent stem cells (iPS) or hematopoietic stem cells (HSCs) comprising a CAR, the CAR comprising an extracellular antigen binding domain that binds to a tumor antigen or a tumor microenvironment (TME) antigen, a transmembrane domain, and a first intracellular signaling domain comprising the cytoplasmic tail of CD40 fused to a second intracellular signaling domain comprising the intracellular domain of CD3ζ. The present invention also relates to therapeutic uses thereof.

This application relates to the biomedical technology field, and more specifically to a tumor therapy method combining recombinant oncolytic viruses and small molecule anticancer drugs. Specifically, it includes the step of treating a tumor using recombinant oncolytic viruses and small molecule anticancer drugs in combination, wherein the small molecule anticancer drugs include ALK-targeting small molecule anticancer drugs, BTK-targeting small molecule anticancer drugs, EGFR-targeting small molecule anticancer drugs, FGFR-targeting small molecule anticancer drugs, HER2-targeting small molecule anticancer drugs, Parp-targeting small molecule anticancer drugs, PI3K-targeting small molecule anticancer drugs, VEGFR-targeting small molecule anticancer drugs, CDK4 / 6-targeting small molecule anticancer drugs, and KRAS-targeting small molecule anticancer drugs, and the recombinant oncolytic viruses include site-directed mutagenesis of M protein, G protein, N protein, P protein, and L protein. In this application, it is possible to achieve an effect greater than 1+1 by using recombinant oncolytic viruses and low-molecular-weight anticancer drugs in combination to attack and kill tumor cells.